Hemant Dhamne
We are currently living in the era of gene modified cell therapies. The field is moving with an exponential pace as multiple clinical trial data is showing promising results and global regulatory agencies like EMA, FDA have approved considerable number of products in recent time. The typical autologous CAR-T manufacturing involves isolation of specific immune cells (T cells) at clinical site, then in the laboratory, these cells are reprogrammed with genetic information that turns them into programmable cellular assassins and then grown in numbers in vitro over 2 weeks
